Hmmm, "Prescient has decided to discontinue the latter program at this stage, and thanks MD Anderson for its work. Both parties may seek to revisit the collaboration or consider other opportunities in the future."
Perhaps juggling that extra variable of an intracellular antigen target was going to cost too much to investigate thoroughly.
Ann: June 2023 Quarterly Update and Appendix 4C, page-8
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
